COGNITIVE IMPAIRMENTS IN FUNCTIONAL HYPERPROLACTINEMIA (FHPRL) IN WOMEN OF REPRODUCTIVE AGE DEPENDING ON THE LEVEL AND DURATION OF FHPRL: RESULTS OF A CROSS-SECTIONAL STUDY.
Abstract
Hyperprolactinemia (HPRL) remains one of the most common endocrinopathies of the reproductive system in women of childbearing age, accompanied by menstrual cycle disorders, reproductive dysfunction, and metabolic disturbances [1, 2]. In clinical practice, the functional form of the disease predominates, the diagnosis of which requires a differentiated approach with exclusion of organic causes of prolactin hypersecretion [3, 4]. Despite well-studied effects of hyperprolactinemia on the reproductive system, the question of the influence of elevated prolactin (PRL) levels on the central nervous system and, in particular, on cognitive functions, remains insufficiently covered in domestic and world literature. Existing data indicate possible neurovegetative symptoms, depression, anxiety, and sleep disorders in patients with HPRL [5, 6]. However, specific cognitive deficits, their pathophysiological mechanisms, and correlation with the level and duration of hyperprolactinemia have been studied fragmentarily. In this article, we present our own research conducted at the Research Institute of Endocrinology depending on the level and duration of fHPRL.
References
1. Glezer A., Bronstein M.D. Prolactinomas // Endocrinol Metab Clin North Am. – 2015. – Vol. 44. – P. 71–78.
2. Naliato E.C.O., Farias M.L.F., Braucks G.R. et al. Prevalence of hyperprolactinemia in women with reproductive disorders // Arq Bras Endocrinol Metab. – 2019. – Vol. 63. – P. 412–418.
3. Klibanski A., Towers K., Scangas G. et al. Functional hyperprolactinemia: diagnostic challenges and therapeutic approaches // Nat Rev Endocrinol. – 2021. – Vol. 17. – P. 521–534.
4. Romanenko Yu.V., Melnichenko G.A. Hyperprolactinemia: modern approaches to diagnosis and treatment // Consilium Medicum. – 2022. – No. 7. – P. 54–61.
5. Sonigo C., Bouilly J., Carre N. et al. Hyperprolactinemia and psychiatric disorders: a Systematic review // Psychoneuroendocrinology. – 2020. – Vol. 115. – 104631.
6. Wang A.T., Mullan R.J., Lane M.A. et al. Treatment of hyperprolactinemia: a systematic review and meta-analysis // Syst Rev. – 2012. – Vol. 1. – P. 33.
7. Torner L., Neumann I.D. The brain prolactin system: involvement in stress response adaptations in lactation // Stress. – 2002. – Vol. 5. – P. 249–257.
8. Grattan D.R., Jasoni C.L., Liu X. et al. Prolactin regulation of gonadotropin-releasing hormone neurons to suppress luteinizing hormone secretion in mice // Endocrinology. – 2007. – Vol. 148. – P. 4344–4351.
9. Brown R.S., Piet R., Herbison A.E. et al. Differential actions of prolactin on electrical activity and intracellular signaling in hypothalamic GnRH neurons // J Neuroendocrinol. – 2017. – Vol. 29. – e12455.
10. Torner L., Toschi N., Nava G. et al. Increased hypothalamic vulnerability to oxidative stress in lactating rats // Neuroscience. – 2002. – Vol. 115. – P. 1133–1140.
11. Samson S.L., Hamrahian A.H., Ezzat S. et al. American Association of Clinical Endocrinologists, American College of Endocrinology disease state clinical review: clinical relevance of macroprolactin in the absence or presence of true hyperprolactinemia // Endocr Pract. – 2015. – Vol. 21. – P. 1420–1428.
12. De Sousa S.M., McLachlan R.I. An update on the diagnosis and management of functional hypothalamic amenorrhea // Curr Opin Endocrinol Diabetes Obes. – 2018. – Vol. 25. – P. 377–382.
13. Folstein M.F., Folstein S.E., McHugh P.R. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician // J Psychiatr Res. – 1975. – Vol. 12. – P. 189–198.
14. Tombaugh T.N., McIntyre N.J. The mini-mental state examination: a comprehensive review // J Am Geriatr Soc. – 1992. – Vol. 40. – P. 922–935.
15. Nasreddine Z.S., Phillips N.A., Bédirian V. et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment // J Am Geriatr Soc. – 2005. – Vol. 53. – P. 695–699.
16. Julayanont P., Phillips N., Chertkow H. et al. The Montreal Cognitive Assessment (MoCA): concept and clinical review // Cognitive Screening Instruments. – Springer, 2017. – P. 139–179.
17. Whittaker P.G., Bersak D., Molitch M. et al. The dopamine-mediated control of prolactin secretion // Endocr Rev. – 2019. – Vol. 40. – P. 1098–1120.
18. Ben-Jonathan N., LaPensee C.R., LaPensee E.W. What can we learn from rodents about prolactin in humans? // Endocr Rev. – 2008. – Vol. 29. – P. 1–41.
19. Grattan D.R. The neuroendocrinology of prolactin: a 45-year perspective // J Neuroendocrinol. – 2020. – Vol. 32. – e12822.
20. Freeman M.E., Kanyicska B., Lerant A. et al. Prolactin: structure, function, and regulation of secretion // Physiol Rev. – 2000. – Vol. 80. – P. 1523–1631.
21. Pires A., Pires A., Ribeiro R. et al. Cognitive performance in patients with hyperprolactinemia: a systematic review // Endocr Connect. – 2021. – Vol. 10. – R109–R117.
22. Alos N., Moliner-Pregel M., Cañete R. et al. Effect of prolactin on glucose and lipid metabolism // Obesity (Silver Spring). – 2009. – Vol. 17. – P. 1334–1337.
23. Serri O., Beauregard C., Rasio E. et al. Metabolic effects of prolactin: a focus on glucose homeostasis and lipid metabolism // Diabetologia. – 2021. – Vol. 64. – P. 2031–2040.
24. Dos Santos Silva C.M., Barbosa F.R., Lima G.A. et al. Body composition and insulin resistance in patients with hyperprolactinemia // Pituitary. – 2011. – Vol. 14. – P. 186–192.
25. Anagnostis P., Adamidou F., Slavakis A. et al. Hyperprolactinemia and cardiovascular risk in patients with prolactinomas // Hormones (Athens). – 2013. – Vol. 12. – P. 415–423.
26. Dejager S., Gerber D., Ducluzeau P.H. et al. Prolactin and cardiovascular risk in patients with prolactinoma // Ann Endocrinol (Paris). – 2010. – Vol. 71. – P. 502–509.
27. Costa A., Riedemann A., Román R. et al. Cognitive dysfunction in patients with hyperprolactinemia // Endocrine. – 2018. – Vol. 59. – P. 111–119.
28. Yamamoto Y., Kato Y., Shimatsu A. et al. Structural brain abnormalities in patients with hyperprolactinemia // J Clin Endocrinol Metab. – 2019. – Vol. 104. – P. 5234–5242.
29. Ferrero A., Barrai I., Davalli M. et al. Cognitive impairment in patients with prolactinomas: a multicenter prospective study // Pituitary. – 2020. – Vol. 23. – P. 245–253.
30. De Sousa S.M., Zhornitzki T., Kahn J.P. et al. Prolactin and dopamine: their relationship in health and disease // Neuroendocrinology. – 2021. – Vol. 111. – P. 1029–1045.
31. Kharlip J., Salvatori R., Yenokyan G. et al. Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy // J Clin Endocrinol Metab. – 2012. – Vol. 97. – P. 720–727.
32. Glezer A., Bronstein M.D. Approach to the patient with persistent hyperprolactinemia and negative sellar imaging // J Clin Endocrinol Metab. – 2012. – Vol. 97. – P. 2211–2216.
33. Molitch M.E. Prolactinoma // N Engl J Med. – 2014. – Vol. 371. – P. 2169–2176.
34. Stojanovic M., Lalic N.M. Cognitive dysfunction in hyperprolactinemia: a review of the literature // Horm Metab Res. – 2022. – Vol. 54. – P. 701–708.
